Market Place
Sourcing Support
Praxis Precision Medicines Announces Inducement Grants
02 Apr 2026 //
GLOBENEWSWIRE
Praxis Precision Medicines Updates Corporate Progress
19 Feb 2026 //
GLOBENEWSWIRE
SEQSTER Expands Partnership With Praxis Precision Medicines
02 Feb 2026 //
BUSINESSWIRE
Praxis Precision Medicines Names Devinsky Clinical Strategy Head
13 Jan 2026 //
GLOBENEWSWIRE
Praxis Precision Medicines Plans Public Offering
06 Jan 2026 //
GLOBENEWSWIRE
Praxis Precision Medicines To Submit NDA For Relutrigine
11 Dec 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines to Participate in Fireside Chat
20 Nov 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines, Announces Proposed Public Offering
16 Oct 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Joins Fireside Chat
29 Aug 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Issues Inducement Grants
06 Aug 2025 //
GLOBENEWSWIRE
Praxis Precision`s Vormatrigine excels in Focal Onset Seizures
04 Aug 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Updates on Q2 2025 Financial Results
04 Aug 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Joins Upcoming Fireside Chat
04 Aug 2025 //
GLOBENEWSWIRE
FDA Grants Praxis Precision Medicines Breakthrough Therapy
17 Jul 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Announces Inducement Grants
02 Jul 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines to Participate in Upcoming Conferences
20 May 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Updates on Q1 2025 Financials
02 May 2025 //
GLOBENEWSWIRE
Praxis Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
02 May 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines Virtual Event on Clinical Programs
08 Apr 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines to Join April Conferences
03 Apr 2025 //
GLOBENEWSWIRE
Praxis To Participate In Five Upcoming Investor Conferences
04 Mar 2025 //
GLOBENEWSWIRE
Praxis Precision Announce Inducement Grants Under Nasdaq 5635(c)(4)
04 Feb 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines to Present at feb Investor Conferences
03 Feb 2025 //
GLOBENEWSWIRE
Praxis Highlights 2025 Corporate Strategy & Business Priorities
12 Jan 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines to Present at J.P. Morgan Conference
06 Jan 2025 //
GLOBENEWSWIRE
Praxis Precision to Present at December Investor Conferences
03 Dec 2024 //
GLOBENEWSWIRE
Praxis to Showcase Update from Epilepsy Pipeline at AES 2024
26 Nov 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Reports Q3 2024 Financials & Updates
06 Nov 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines to Attend 3 Nov Investor Conferences
06 Nov 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines to Report Q3 2024 Results on Nov 6
01 Nov 2024 //
GLOBENEWSWIRE
Praxis Presents On Ulixacaltamide At Movement Disorders Congress
26 Sep 2024 //
GLOBENEWSWIRE
Praxis` Na+ channel blocker reduces seizures in 2 types of epilepsy in phase 2
03 Sep 2024 //
GLOBENEWSWIRE
Praxis: Nasdaq Inducement Grants Announced
04 Jun 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
17 May 2024 //
GLOBENEWSWIRE
Praxis Provides Update, Reports Q1 2024 Financial Results
13 May 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Q1 2024 Results On May 13
10 May 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Reports Nasdaq Listing Inducement Grants
03 May 2024 //
GLOBENEWSWIRE
Praxis At AAN On Ulixacaltamide
12 Apr 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines to Participate in Upcoming April Conferences
05 Apr 2024 //
GLOBENEWSWIRE
Praxis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Apr 2024 //
GLOBENEWSWIRE
Praxis Precision Announces Pricing of $200 Million Public Offering
28 Mar 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
27 Mar 2024 //
GLOBENEWSWIRE
Praxis Positive Results of PRAX-628 Study Evaluating PPR Achieving 100% Response
26 Mar 2024 //
GLOBENEWSWIRE
Praxis’ epilepsy drug hits in phase 2, sparking stock rise
26 Mar 2024 //
FIERCE BIOTECH
Praxis Precision Medicines to Host PRAX-628 Program Update
25 Mar 2024 //
GLOBENEWSWIRE
Praxis Precision Reports Fourth Quarter and Full-Year 2023 Financial Results
05 Mar 2024 //
GLOBENEWSWIRE
Praxis Precision to Participate in TD Cowen™s 44th Annual Health Care Conference
01 Mar 2024 //
GLOBENEWSWIRE
Praxis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Announces Pricing of $150.0 Million Public Offering
11 Jan 2024 //
GLOBENEWSWIRE
Praxis prices $150M public stock offering
11 Jan 2024 //
ENDPTS
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
10 Jan 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
08 Jan 2024 //
GLOBENEWSWIRE
Praxis Precision Announces Collaboration Agreement with Tenacia
05 Jan 2024 //
GLOBENEWSWIRE
Praxis Precision to Showcase Largest Pipeline of Precision Epilepsy Programs
28 Nov 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines to Present at the Piper Sandler 35th Conference
21 Nov 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
02 Oct 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
27 Sep 2023 //
GLOBENEWSWIRE
Praxis Precision to Present at H.C. Wainwright 25th Annual Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
Praxis Precision to Present Data from Epilepsy Portfolio at the 35th Congress
31 Aug 2023 //
GLOBENEWSWIRE
